Literature DB >> 20609311

Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in vitro.

Jesús Sánchez-Más1, María C Turpín, Antonio Lax, Juan A Ruipérez, Mariano Valdés Chávarri, Domingo A Pascual-Figal.   

Abstract

INTRODUCTION AND
OBJECTIVES: Testosterone deficiency is associated with a poor prognosis in patients with heart failure. It is not clear whether testosterone reduces cardiomyocyte apoptosis or whether the effect of spironolactone, an aldosterone receptor blocker with progestogenic and anti-androgen activity, differs from that of the selective aldosterone blocker eplerenone.
METHODS: Apoptosis induced by hyperosmotic stress in the embryonic rat heart cell line H9c2 was monitored by measuring cell viability, DNA fragmentation and caspase-3, -8 and -9 activation. The effect of testosterone was investigated in the presence or absence of spironolactone and eplerenone.
RESULTS: Exposure to sorbitol (0.6 M, 3 h) decreased cell viability and increased DNA fragmentation and caspase-3, -8 and -9 activation. These effects were all significantly reduced by testosterone, 100 nM (P< .01). Pretreatment with spironolactone, 10 .M, blocked the effects of testosterone, decreased cell viability (P< .01) and increased caspase activation (P< .01). In contrast, eplerenone, 10 .M, increased cell viability (P< .001) without altering the effect on caspase activation. These actions were not modified by the androgen receptor blocker flutamide. They were mediated by SAPK/JNK and ERK1/2 signaling pathways (P< .01).
CONCLUSIONS: Testosterone appears to have a protective effect against cardiomyocyte apoptosis which is antagonized by spironolactone but not by eplerenone. These effects await confirmation in in vivo models, but their presence could have clinical and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609311     DOI: 10.1016/s1885-5857(10)70162-6

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  4 in total

1.  Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression.

Authors:  Javad Habibi; Vincent G DeMarco; Lixin Ma; Lakshmi Pulakat; William E Rainey; Adam T Whaley-Connell; James R Sowers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-14       Impact factor: 4.733

2.  Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study.

Authors:  L Frankenstein; H A Katus; M Grundtvig; T Hole; J de Blois; D Schellberg; D Atar; C Zugck; S Agewall
Journal:  Eur J Clin Pharmacol       Date:  2013-06-07       Impact factor: 2.953

3.  The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction.

Authors:  Evangelos Mavrommatis; Krystyna M Shioura; Tamara Los; Paul H Goldspink
Journal:  Mol Cell Biochem       Date:  2013-05-28       Impact factor: 3.396

4.  Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.

Authors:  Elisa Ramírez; Mercedes Klett-Mingo; Sara Ares-Carrasco; Belén Picatoste; Alessia Ferrarini; Francisco J Rupérez; Alicia Caro-Vadillo; Coral Barbas; Jesús Egido; José Tuñón; Óscar Lorenzo
Journal:  Cardiovasc Diabetol       Date:  2013-11-21       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.